Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vistin Pharma ASALTS:0RAM 73 3-Year FCF Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates LTS:0RAM with a GF Score™ of 73/100 and a GF Value™ of kr25.98 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 660 Drug Manufacturers companies, Vistin Pharma ASA ranks worse than 151515% on this metric.
During the past 12 months, Vistin Pharma ASA's average Free Cash Flow per Share Growth Rate was -35.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Vistin Pharma ASA was 42.40% per year. The lowest was -81.80% per year. And the median was -3.85% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Vistin Pharma ASA 3-Year FCF Growth Rate Related Terms
LTS:0RAM vs ZTS, UTHR, VTRS: 3-Year FCF Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA 3-Year FCF Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
Vistin Pharma ASA (LTS:0RAM) has a 3-Year FCF Growth Rate of 0.00% as of Mar. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Vistin Pharma ASA and its competitors. According to the industry distribution chart, Vistin Pharma ASA ranks #999999 out of 660 companies in the Drug Manufacturers industry.
Is Vistin Pharma ASA's 3-Year FCF Growth Rate too high?
Vistin Pharma ASA's current 3-Year FCF Growth Rate is 0.00%. Based on the distribution chart, Vistin Pharma ASA ranks #999999 out of 660 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vistin Pharma ASA has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's 3-Year FCF Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #999999 out of 660 companies for 3-Year FCF Growth Rate. This places Vistin Pharma ASA in the lower half of its industry. The industry median 3-Year FCF Growth Rate is 8.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Drug Manufacturers company?
The median 3-Year FCF Growth Rate among Drug Manufacturers companies is 8.75, based on 660 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median 3-Year FCF Growth Rate is 8.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current 3-Year FCF Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.98, compared to a current price of kr20.00 — trading 23% below its estimated fair value. The current 3-Year FCF Growth Rate is 0.00%. Vistin Pharma ASA's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current 3-Year FCF Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.00 is trading 23% below its estimated GF Value™ of kr25.98.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
3-Year FCF Growth Rate: 0.00%
GF Value™: kr25.98 vs. price of kr20.00 (23% below fair value)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
73GF Score
Get the complete analysis for LTS:0RAM
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 
